SBBP News and Press, Strongbridge Biopharma plc From 08/05/21

~ Reports KEVEYIS ® (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~ ~ Strongbridge Remains On-Track to Meet, or Potentially Exceed, the Top End ...

Corcept Therapeutics Incorporated is working to improve on Korlym, its cortisol regulator and sole source of its $350 million plus top line, with next-generation relacorilant. In addition to Cushing’s Syndrome, relacorilant has demonstrated statistically significant efficacy in...

DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“ Strongbridge ”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with signi...

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“ Strongbridge ”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with signi...

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...

DUBLIN, Ireland and TREVOSE, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th...

ALACHUA, Fla. and TAMPA, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its Board of D...

Welbilt receives a second more lucrative offer from the Ali Group that is well above the current all-stock deal with Middleby. Regulatory agencies flex their muscles with China’s antitrust regulator blocking Tencent Holdings’ plan to merge Huya and DouYu. EU approves...

Strongbridge Biopharma (SBBP) announces that post hoc analyses from a one year open-label study evaluating daily use of KEVEYIS (dichlorphenamide) for the treatment of Primary Periodic Paralysis ((PPP)) following a nine-week randomized, controlled study were published in the peer-reviewed jou...

~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~ ~ Analyses Provide Potentially Useful Information to Help Guide Clinician Patient Counseling & Management When Starting Treatment with KEVEYIS ~ DUBLIN, Ireland and TREVOSE, Pa., ...